Hybrid coronary revascularization for the treatment of coronary artery disease

Hybrid coronary revascularization (HCR) combines the respective strengths of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for selected patients with multivessel coronary artery disease. HCR includes the minimally invasive direct coronary artery bypass of a left internal thoracic artery graft to the left anterior descending artery (LAD) with stenting of non-LAD lesions with PCI, in onestop or staged hybrid procedures.HCR can prove superiority to conventional CABG in clinical complications. Many available data suggests that HCR is feasible and safe in skilled hands. Further large-scale randomized controlled trials are in great need. HCR may become another more commonly used interventional strategy for certain patients with multivessel coronary artery disease.